Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.

ESPR

Esperion Therapeutics (ESPR)

Esperion Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:ESPR
FechaHoraFuenteTítuloSímboloCompañía
25/09/202415:30GlobeNewswire Inc.Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:ESPREsperion Therapeutics Inc
18/09/202415:12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ESPREsperion Therapeutics Inc
17/09/202415:02Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ESPREsperion Therapeutics Inc
05/09/202407:00GlobeNewswire Inc.Esperion to Participate in Upcoming 2024 Cantor Global Healthcare ConferenceNASDAQ:ESPREsperion Therapeutics Inc
03/09/202407:00GlobeNewswire Inc.Esperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe)NASDAQ:ESPREsperion Therapeutics Inc
26/08/202407:00GlobeNewswire Inc.Esperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:ESPREsperion Therapeutics Inc
12/08/202415:33Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ESPREsperion Therapeutics Inc
12/08/202415:08Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ESPREsperion Therapeutics Inc
12/08/202406:21Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ESPREsperion Therapeutics Inc
12/08/202405:00GlobeNewswire Inc.Esperion Reports Second Quarter 2024 Financial Results and Provides a Business UpdateNASDAQ:ESPREsperion Therapeutics Inc
12/08/202404:47IH Market NewsU.S. Futures Steady as Markets Await Key Inflation Data, Oil Prices ClimbNASDAQ:ESPREsperion Therapeutics Inc
07/08/202415:30GlobeNewswire Inc.Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:ESPREsperion Therapeutics Inc
25/07/202407:00GlobeNewswire Inc.Esperion to Report Second Quarter 2024 Financial Results on August 12NASDAQ:ESPREsperion Therapeutics Inc
24/07/202407:00GlobeNewswire Inc.Esperion to Participate in Upcoming BTIG Biotech ConferenceNASDAQ:ESPREsperion Therapeutics Inc
16/07/202407:00GlobeNewswire Inc.New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the “Lipid Lurkers” Inside Their ArteriesNASDAQ:ESPREsperion Therapeutics Inc
28/06/202406:00GlobeNewswire Inc.Esperion Announces Monetization of European Royalties and Concurrent Payoff and Termination of Existing Revenue Interest FacilityNASDAQ:ESPREsperion Therapeutics Inc
23/05/202408:00GlobeNewswire Inc.Esperion to Participate in Upcoming June Investor ConferencesNASDAQ:ESPREsperion Therapeutics Inc
22/05/202407:00GlobeNewswire Inc.First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular RiskNASDAQ:ESPREsperion Therapeutics Inc
20/05/202405:00GlobeNewswire Inc.Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for HypercholesterolemiaNASDAQ:ESPREsperion Therapeutics Inc
14/05/202407:00GlobeNewswire Inc.Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET®NASDAQ:ESPREsperion Therapeutics Inc
07/05/202405:00GlobeNewswire Inc.Esperion Reports First Quarter 2024 Financial ResultsNASDAQ:ESPREsperion Therapeutics Inc
29/04/202407:00GlobeNewswire Inc.Esperion to Participate in Upcoming May Investor ConferencesNASDAQ:ESPREsperion Therapeutics Inc
23/04/202407:00GlobeNewswire Inc.Esperion to Report First Quarter 2024 Financial Results on May 7NASDAQ:ESPREsperion Therapeutics Inc
07/04/202413:45GlobeNewswire Inc.Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with ObesityNASDAQ:ESPREsperion Therapeutics Inc
01/04/202407:00GlobeNewswire Inc.Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024NASDAQ:ESPREsperion Therapeutics Inc
26/03/202407:00GlobeNewswire Inc.Esperion to Participate in 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:ESPREsperion Therapeutics Inc
25/03/202415:00GlobeNewswire Inc.Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24NASDAQ:ESPREsperion Therapeutics Inc
22/03/202417:26Business WireU.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin UseNASDAQ:ESPREsperion Therapeutics Inc
22/03/202414:10GlobeNewswire Inc.U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin UseNASDAQ:ESPREsperion Therapeutics Inc
22/03/202410:04GlobeNewswire Inc.CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular EventsNASDAQ:ESPREsperion Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ESPR

Su Consulta Reciente

Delayed Upgrade Clock